Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Chicken Soup for the Busy Coordinator September 2009.
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS & INCIDENTS OF NON-COMPLIANCE ( AKA PROTOCOL DEVIATIONS ) TRACY RIGHTMER, JD, CIP COMPLIANCE.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
Unanticipated Problems Involving Risk to Subjects or Others (UPIRSO) Roy R. Estrada, PhD, PA-C, CIP Associate Director IRB UTHSCSA.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
1 © Huron Consulting Group Inc. All rights reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,
Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs
Capturing and Reporting Adverse Events in Clinical Research
Director, Investigator Support & Integration Services, OCTRI
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Vanderbilt Human Research Protections Program
Overview of Good Clinical Practices (GCPs)
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
AAHRPP Accreditation Karen L. Smarr, PhD Human Research Compliance Officer Truman VA Hospital, Columbia, MO Cincinnati, OH March 19, 2007.
Paula Peyrani, MD Division of Infectious Diseases University of Louisville Performing the Study.
Using the short form and reporting adverse events Erin Coons, Senior IRB Specialist, COMIRB 1.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
New Adverse Event Reporting Policy Effective September 1, 2007.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
Investigational New Drug Application (IND)
Institutional Review Board (IRB) for Human Subject Protections: Working with the IRB Erin McClure, PhD Department of Psychiatry and Behavioral Sciences.
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Teaching Research Methods (Classroom Protocols) Boston University Charles River Campus Boston University Medical Center Mary A. Banks BS, BSN IRB Director.
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements Revised May 21, 2010 (Presentation prepared for HRPP 101,
TERRENCE F. ACKERMAN, PH.D. PROFESSOR OF BIOETHICS CHAIR, UTHSC IRB.
THE ROLE OF DSMB’s in CLINICAL RESEARCH Data and Safety Monitoring Monitoring.
Understanding Unanticipated Problems (UPs) Elizabeth Ness, RN, MS Director, Staff Development Office of the Clinical Director Center for Cancer Research,
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
1 Unanticipated problems Melody Lin, Ph.D. December,
Office of Research Oversight 1 Office of Research and Development Local Accountability Meeting January 2009.
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Houston, We have a Problem: When and How to Report Problems to the IRB.
Institutional Review Board (IRB) for Human Subject Protections: Working with the IRB Erin A McClure, PhD Department of Psychiatry and Behavioral Sciences.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
Main Line Hospitals Institutional Review Board Unanticipated Problems Anne Marie Hobson, BSN, JD, ORA Director Theresa Greaves, ORA Manager.
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
Reportable Events Emory IRB 9/11/2014.
IRB reporting updates.
What is a Data and Safety Monitoring Plan and how do I get one?
Reportable Events & Other IRB Updates February 2017
Adverse Event Reporting: Trials and Tribulations
Pharmacovigilance in clinical trials
THE ROLE OF DSMB’s in CLINICAL RESEARCH
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Reportable Events & Revised Common Rule
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
UVM Research Protections Office
HHS Reporting Requirements and Adverse Events
Event Reporting in Human Subjects Research
Policy on Prompt Reporting
Presentation transcript:

Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)

Difference between UPIRSO and SAE? What is UPIRSO? A UPIRSO includes any adverse event, incident, experience, or outcome that meets all of the following criteria: Unexpected (in terms of nature, severity, or frequency) given: – the research procedures that are described in the protocol-related documents, such as the IRB approved research protocol and informed consent document; and – the characteristics of the subject population being studied. 1. The known or foreseeable risk of adverse events associated with the procedures involved in the research that are described in: a) the protocol-related documents, such as the IRB- approved research protocol, any applicable investigator brochure, and the current IRB- approved informed consent document; and b) other relevant sources of information, such as product labeling and package inserts; or 2. The expected natural progression of any underlying disease, disorder, or condition of the subject(s) experiencing the adverse event and the subject's predisposing risk factor profile for the adverse event. Related or possibly related to a subject's participation in the research; and Suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. What is Serious Adverse Event (SAE)? The following events are considered a serious adverse event and would place subjects at a greater risk of harm: results in death; is life-threatening (places the subject at immediate risk of death from the event as it occurred); results in inpatient hospitalization or prolongation of existing hospitalization; results in a persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; or based upon appropriate medical judgment, may jeopardize the subject’s health and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition (examples of such events include allergic bronchospasm requiring intensive treatment in the emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse). **It is important to note that an event may not actually cause any physical, psychological, social, or economic harm to a research subject or another person, but nevertheless, meets the definition of a UPIRSO. In such cases, the UPIRSO still must be reported to the IRB.

Difference between UPIRSO and AE? UPIRSO UPIRSO is an unanticipated event and may involve the increased risk of harm— whether or not any actual harm occurred Adverse Event (AE) “adverse event” ('AE') may be anticipated or unanticipated

Determining whether an event is a UPIRSO

Examples of UPIRSOs: Investigator finds out that the study involves a currently approved drug that may cause renal failure according to newly published literature. An interim analysis or safety monitoring report that indicates that frequency or magnitude of harms or benefits may be different than those initially presented to the IRB. The PI finds out that one of his subjects has become incarcerated. His project is not currently approved by the IRB to enroll prisoners. Investigator realizes subjects have been accidentally given study drug at a higher dose than was approved by the IRB. While no side effects were reported, the increase in dosage placed the subjects at potential risk of harm. A computer or other electronic device is stolen that contained identifiable subject information. 4 weeks into the study of a new asthma drug, the subject informs the research staff that she is pregnant although the pregnancy test done at screening had come back negative. Pregnancy is an exclusion factor in the study. A researcher has IRB approval to obtain written consent for a survey study to be conducted in women who live in a remote village in Ghana. Only after getting to the village does he realize that most of the women are unable to read or write in English. Since he is short on time and does not have ready access to computers, he chooses to obtain oral consent without first obtaining IRB approval.

Examples of events that are not adverse events, but are UPIRSOs Example 1 An investigator conducting behavioral research collects individually identifiable sensitive information about illicit drug use and other illegal behaviors by surveying college students. The data are stored on a laptop computer without encryption, and the laptop computer is stolen from the investigator’s car on the way home from work. This is an unanticipated problem that must be reported because the incident was (a) unexpected (i.e., the consent document and IRB-approved protocol or NPSF did not anticipate the theft as an expected risk of participation); (b) the event was related to participation in the research; and (c) the event placed the subjects at a greater risk of psychological and social harm because of the breach in confidentiality of the study data. Explanation The events described in the example were unexpected in nature, related to participation in the research, and resulted in new circumstances that increased the risk of harm to subjects. The unanticipated problems warranted consideration of substantive changes in the research protocol or informed consent process/document or other corrective actions in order to protect the safety, welfare, or rights of subjects. While these events may not have caused any detectable harm or adverse effect to subjects or others, they nevertheless represent unanticipated problems and should be promptly reported to the IRB, appropriate institutional officials, the supporting agency head and OHRP in accordance with HHS regulations.

Examples of events that are not adverse events, but are UPIRSOs Example 2 As a result of a processing error by a pharmacy technician, a subject enrolled in a multicenter clinical trial receives a dose of an experimental agent that is ten times higher than the dose indicated in the IRB-approved protocol. While the dosing error increased the risk of toxic manifestations of the experimental agent, the subject experienced no detectable harm or adverse effect after an appropriate period of careful observation. Nevertheless, this constitutes an unanticipated problem for the institution where the dosing error occurred that must be reported to the IRB, because the incident was (a) unexpected; (b) related to participation in the research; and (c) placed subject at a greater risk of physical harm than was previously known or recognized. Explanation The events described in the example were unexpected in nature, related to participation in the research, and resulted in new circumstances that increased the risk of harm to subjects. The unanticipated problems warranted consideration of substantive changes in the research protocol or informed consent process/document or other corrective actions in order to protect the safety, welfare, or rights of subjects. While these events may not have caused any detectable harm or adverse effect to subjects or others, they nevertheless represent unanticipated problems and should be promptly reported to the IRB, appropriate institutional officials, the supporting agency head and OHRP in accordance with HHS regulations.

Examples of events that are not adverse events, but are UPIRSOs Example 3 Subjects with cancer are enrolled in a phase 2 clinical trial evaluating an investigational biologic product derived from human sera. After several subjects are enrolled and receive the investigational product, a study audit reveals that the investigational product administered to subjects was obtained from donors who were not appropriately screened and tested for several potential viral contaminants, including the human immunodeficiency virus and the hepatitis B virus. This constitutes an unanticipated problem that must be reported because the incident was (a) unexpected; (b) related to participation in the research; and (c) placed subjects and others at a greater risk of physical harm than was previously known or recognized. Explanation The events described in the example were unexpected in nature, related to participation in the research, and resulted in new circumstances that increased the risk of harm to subjects. The unanticipated problems warranted consideration of substantive changes in the research protocol or informed consent process/document or other corrective actions in order to protect the safety, welfare, or rights of subjects. In addition, this third example may have presented unanticipated risks to others (e.g., the sexual partners of the subjects) in addition to the subjects. While these events may not have caused any detectable harm or adverse effect to subjects or others, they nevertheless represent unanticipated problems and should be promptly reported to the IRB, appropriate institutional officials, the supporting agency head and OHRP in accordance with HHS regulations

UPIRSO Regulations: FDA 21CFR56.108(b) Title 21-Food and Drugs Part 56-Institutional Review Board Sec IRB functions and operations In order to fulfill the requirements of these regulations, each IRB shall: (b) Follow written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the food and Drug Administration of: (1) any unanticipated problems involving risks to human subjects or others; (2) any instance of serious or continuing noncompliance with these regulations or the requirements of determinations of the IRB; or (3) any suspension or termination of IRB approval

UPIRSO Regulations: HHS 45CFR46.103(b)(5) Title 45-Public Welfare Part 46-Protection of Human Subjects Sec Assuring compliance with this policy-research conducted or supported by any Federal Department or Agency b)Departments and agencies will conduct or support research covered by this policy only if the institution has an assurance approved as provided in this section, and only if the institution has certified to the department of agency head that the research has been reviewed and approved by an IRB provided for in the assurance, and will be subject to continuing review by the IRB. Assurances applicable to federally supported or conducted research shall at a minimum include: (5) Written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the department or agency head of (i) any unanticipated problems involving risks to subject or others or any serious or continuing noncompliance with this policy or the requirements or determinations of the IRB and (ii) any suspension or termination of IRB approval

UPRISO Regulations: International of Conference on Harmonization (ICH) 4.11